复星医药控股子公司拟筹划转让上海克隆100%股权

Core Viewpoint - Fosun Pharma plans to divest 100% equity of Shanghai Clone to focus on core business and enhance asset operation efficiency [1] Group 1: Company Actions - Fosun Pharma's subsidiary intends to transfer 100% equity of Shanghai Clone, aiming to streamline operations [1] - The company will invest 54.6 million RMB as a limited partner in a special fund alongside Hongyi Tianjin and Zhonghui Life Insurance [1] - The expected transfer value for the equity and related debts of Shanghai Clone is up to 1.256 billion RMB [1]